Jump to content
Applications | Genedata Biologics

Overcome Barriers in Biologics-Based Discovery

Drive innovation across all biotherapeutic applications including antibodies, bispecifics, ADCs, TCRs, and CAR-Ts.

Choose Your Application
Bispecifics

Bispecifics

Vaccines

Vaccines

CARs/TCRs

CARs/TCRs

AAVs

AAVs

ADCs

ADCs

B Cells

B Cells

Developability

Developability

Immuno-oncology. Yeast and phage display. Hybridoma and B-cells. Molecular design. Cell and gene therapies. Developability and manufacturability assessments. Genedata Biologics® comes with purpose-built, ready-to-use functionalities for all applications across biopharma discovery.

Bispecific Antibody Engineering

Bispecific Antibody Engineering

Genedata Biologics enables the systematic design, cloning, and testing of large numbers of bi- and multi-specifics, such as knobs-into-holes (KinH), Fab-scFv, IgG-scFv, DuoBody, DVD-Ig, tandem-scFv-Fc and their parametric variants (e.g., linkers, V-domain order, Fc). It also automates downstream expression, purification, and characterization processes, which substantially increases throughput. By identifying the most successful combination of antigen binders and formats, the platform resolves major bottlenecks in high-throughput molecular biology and cloning processes and directly integrates with laboratory automation equipment to scale up cloning and production. With the automatic aggregation of all assay and analytics results, the platform also enables multi-parameter lead selection.

Vaccine Discovery

Vaccine Discovery

Designed to increase the efficiency and quality of vaccine discovery, the purpose-built, end-to-end enterprise platform supports the full discovery process and enables faster testing, simplified production, and reduced costs. In addition to classical vaccine R&D approaches, it supports novel vaccine technologies such as synthetic self-amplifying mRNA, which accelerates vaccine development by utilizing synthetic and cell-free processes. Genedata Biologics paves the way for the discovery of novel vaccines, even for antigens that are extremely difficult to produce and formulate.

Learn More
CAR-Ts & TCRs

CAR-Ts & TCRs

With purpose-built functionalities for the design and evaluation of large panels of cell-based therapeutic modalities for novel immunotherapies, such as chimeric antigen receptors T cells (CAR-T), T Cell Receptor Technology (TCRs), and antibody TCR-mimetics, Genedata Biologics enables the systematic engineering, production, and testing of novel therapeutic modalities. The platform streamlines the full process from design, generation, testing, and validation, to developability and manufacturability assessments. By directly integrating with laboratory equipment, it fully automates sample handling and testing procedures. An integrated database and tools support screening and engineering of a variety of TCR-based formats (e.g., dsTCR, TCR-scFv, bispecific TCRs).

AAVs

AAVs & Gene Therapy

Genedata Biologics is the leading workflow platform for increasing the efficiency of gene therapy R&D, supporting diverse viral delivery systems including adeno-associated virus (AAV), adenovirus, and retrovirus vectors. The platform covers the entire gene therapy workflow, from serotype optimization and viral vector design to virus packaging, purification, and testing. It tracks all samples and associated information including customized vectors and packaging plasmids, cell lysates, purified virus batches and their sequences, titers, and assay results such as empty-to-full capsid ratios. Genedata Biologics provides valuable, real-time insights leading to improved quality control, assay standardization, and more accurate viral potency assessments, putting all critical decision factors in one place to facilitate scale-up and reproducibility during vector manufacturing.

ADC Design, Engineering & Testing

ADC Design, Engineering & Testing

The discovery and development process for Antibody Drug Conjugates (ADCs), or immunoconjugates, is complex and poses significant challenges. Genedata Biologics supports the full ADC discovery process from antibody screening and engineering, to antibody expression, purification, drug conjugation, and reporting of ADC-specific analytics (e.g., DAR, drug distribution, homogeneity). The platform enables the registration and tracking of large panels of ADC candidates and manages all linker and payload information (e.g., cytotoxic small molecules). By incorporating results from analytics and functional assays in one integrated platform, Genedata Biologics substantially increases throughput and efficiency in ADC discovery.

Lead Discovery from B Cells

Lead Discovery from B Cells

Genedata Biologics provides application-ready functionalities that significantly increase the throughput and quality of B cell-derived therapeutic antibody candidates. The platform streamlines every stage of the highly complex B cell-based discovery process by tracking animal and immunization data to register all molecules, samples, and assay data created along B cell workflows. It tracks and monitors the complete history of the antibody clones, which undergo multiple format changes from B cells to PCR products, plasmids, and transfected cells. Quality control and functional assay data, such as ELISA, FACS, and SPR experiments, are managed in one integrated platform. In combination with V-region sequencing results, this allows the unique integration of molecule sequence and functional information and helps research teams make informed decisions on lead candidates to prioritize and move forward.

Developability & Manufacturability

Developability & Manufacturability

Genedata Biologics enables the systematic assessment of a candidate’s developability risk profile and critical quality attributes (CQA) to decide on the most promising development candidates. Common problems identified include aggregation issues, formulation instability, and reduced pharmacological activity. In addition, the platform assesses the drug’s manufacturability in terms of potential problems such as those during expression and purification. Genedata Biologics also evaluates properties that affect molecule robustness on a biophysical and biochemical level. Typical tests include stability (e.g., pH, freeze-thaw, high- and low-temperature stability tests), degradation (e.g., resulting from extreme pH values, light, oxidation), viscosity, thermal stability, solubility, glycosylation characterization, and immunogenicity. The platform evaluates intrinsic molecular properties that may impact technical development and comes with built-in tools to enable a systematic and holistic assessment of all drug candidates to minimize future development and manufacturing risks.

Innovating Across All Biotherapeutic Applications

Get Started